Prostate cancer targeting motifs: Expression of α vβ 3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts

Prostate

Volumn 72, Issue 5, 2012, Pages 523-532

  Taylor, Robert M ^a   Severns, Virginia ^a   Brown, David C ^a   Bisoffi, Marco ^a,b   Sillerud, Laurel O ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

3; cells versus xenografts; membrane proteins; NTSR1; PSCA; PSMA; tumorigenic potential

Indexed keywords

NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MOTIF; TUMOR MICROENVIRONMENT; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, NEUROTENSIN; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS;

EID: 84857507548     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21454     Document Type: Article

References (39)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; DOI 10.3322/caac.20121
2. Sardana G, Dowell B, Diamandis EP,. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008; 54 (12): 1951-1960.
3. Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT, Vickers AJ, Schroder FH, Lilja H,. A four-kallikrein panel for the prediction of repeat prostate biopsy: Data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. Br J Cancer 2010; 103 (5): 708-714.
4. Studer UE, Collette L,. What can be concluded from the ERSPC and PLCO trial data? Urol Oncol 2010; 28 (6): 668-669.
5. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR,. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998; 159 (4): 1247-1250.
6. Zarour L, Alumkal J,. Emerging therapies in castrate-resistant prostate cancer. Curr Urol Rep 2010; 11 (3): 152-158.
7. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN,. Castration-resistant prostate cancer: Current and emerging treatment strategies. Drugs 2010; 70 (8): 983-1000.
8. Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM,. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008; 3 (3): 311-321.
9. Afnan J, Tempany CM,. Update on prostate imaging. Urol Clin North Am 2010; 37 (1): 23-25 (Table of Contents).
10. Jadvar H,. Molecular imaging of prostate cancer: A concise synopsis. Mol Imaging 2009; 8 (2): 56-64.
11. Chellat F, Merhi Y, Moreau A, Yahia L,. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials 2005; 26 (35): 7260-7275.
12. Adair JH, Parette MP, Altinoglu EI, Kester M,. Nanoparticulate alternatives for drug delivery. ACS Nano 2010; 4 (9): 4967-4970.
13. Serda RE, Adolphi NL, Bisoffi M, Sillerud LO,. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging 2007; 6 (4): 277-288.
14. Taylor RM, Huber DL, Monson TC, Ali AS, Bisoffi M, Sillerud LO,. Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cell lines using both fluorescence and magnetic resonance imaging. J Nanopart Res 2011; Epub: DOI 10.1007/s11051-011-0439-3
15. Sobel RE, Sadar MD,. Cell lines used in prostate cancer research: A compendium of old and new linesPart 1. J Urol 2005; 173 (2): 342-359.
16. Sobel RE, Sadar MD,. Cell lines used in prostate cancer research: A compendium of old and new linesPart 2. J Urol 2005; 173 (2): 360-372.
17. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM,. Molecular imaging of prostate cancer. Methods 2009; 48 (2): 193-199.
18. McCabe NP, De S, Vasanji A, Brainard J, Byzova TV,. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling. Oncogene 2007; 26 (42): 6238-6243.
19. Swift SL, Burns JE, Maitland NJ,. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res 2010; 70 (1): 347-356.
20. Saeki N, Gu J, Yoshida T, Wu X,. Prostate stem cell antigen: A Jekyll and Hyde molecule? Clin Cancer Res 2010; 16 (14): 3533-3538.
21. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW,. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54 (10): 2577-2581.
22. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA,. Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004; 64 (15): 5311-5321.
23. Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, Uhlen M, Nilsson P,. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 2009; 10: 365.
24. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte ON, Said JW, Loda M, Reiter RE,. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000; 19 (10): 1288-1296.
25. Laidler P, Dulinska J, Lekka M, Lekki J,. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005; 435 (1): 1-14.
26. Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB,. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer 2000; 88 (2): 407-415.
27. Raff AB, Gray A, Kast WM,. Prostate stem cell antigen: A prospective therapeutic and diagnostic target. Cancer Lett 2009; 277 (2): 126-132.
28. Zhigang Z, Wenlu S,. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma. Prostate 2005; 65 (4): 299-305.
29. Lakhan SE, Sabharanjak S, De A,. Endocytosis of glycosylphosphatidylinositol-anchored proteins. J Biomed Sci 2009; 16: 93.
30. Hong H, Zhang Y, Sun J, Cai W,. Positron emission tomography imaging of prostate cancer. Amino Acids 2010; 39 (1): 11-27.
31. Stollman TH, Ruers TJ, Oyen WJ, Boerman OC,. New targeted probes for radioimaging of angiogenesis. Methods 2009; 48 (2): 188-192.
32. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM,. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005; 53 (3): 621-627.
33. Liu Z, Wang F, Chen X,. Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev Res 2008; 69 (6): 329-339.
34. Almeida TA, Rodriguez Y, Hernandez M, Reyes R, Bello AR,. Differential expression of new splice variants of the neurotensin receptor 1 gene in human prostate cancer cell lines. Peptides 2010; 31 (2): 242-247.
35. Carraway RE, Plona AM,. Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools. Peptides 2006; 27 (10): 2445-2460.
36. Carraway RE, Hassan S,. Neurotensin receptor binding and neurotensin-induced growth signaling in prostate cancer PC3 cells are sensitive to metabolic stress. Regul Pept 2007; 141 (1-3): 140-153.
37. Wang W, Mo ZN,. Advances in prostate-specific membrane antigen targeted therapies for prostate cancer. Zhonghua Nan Ke Xue 2010; 16 (6): 547-551.
38. Elsasser-Beile U, Buhler P, Wolf P,. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10 (2): 118-125.
39. Bander NH,. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3 (4): 216-225.